The COVID-19 pandemic has caused an alarming rise of an aggressive and highly fatal secondary fungal infection among those with active or recovered COVID-19.
Research suggests that the SARS-CoV-2 virus, the overuse of immunosuppressive COVID-19 treatments such as corticosteroids and antibiotics, and the global pandemic response made people more susceptible to co-infections such as COVID-19-associated mucormycosis (CAM).
